Bridging the preclinical-clinical boundary

The UK has a world-leading research ecosystem for medicines discovery research, which is supported by a multitude of translational infrastructure and targeted funding streams for early-stage clinical research. However, in order to maintain and improve upon this excellence, we need to embrace new models that can improve the translation of research. A key point along the translational pathway is the preclinical-clinical boundary, where innovative research models are likely to have significant impact on improving the efficiency and success of medicines development programmes.

Summary report of a joint workshop held on 9 March 2018 by the Academy of Medical Sciences and the Association of the British Pharmaceutical Industry.